
News|Articles|November 1, 2006
Pipeline Preview (November 2006)
Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers discover new pathway to fight liver inflammation
2
Weekly autoinjector Leqembi is available for treatment initiation in Alzheimer’s
3
BE BOLD Efficacy and Safety Data: Comparing Bimekizumab and Risankizumab on Joint-Centric Endpoints
4
Anti-inflammatories instead of antifungals for seborrheic dermatitis
5














